Princeton Medical Institute

Princeton, New Jersey 08540

1 studies enrolling now · 35 studies all time

What they study most

ADHD, Alzheimer Disease, Alzheimer's Disease, Anxiety Disorder, Atrial Fibrillation, Atrial Flutter, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), Binge-Eating Disorder, Central Nervous System Diseases, Cognition

Studies at this site

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
• A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) — Running, not enrolling
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD — Running, not enrolling
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder — Completed
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression — Completed
• A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder — Completed
• A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD — Completed
• Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD — Completed
• Study of BHV-4157 in Alzheimer's Disease — Completed
• A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease — Completed
• Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease — Completed
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia — Stopped early
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) — Completed
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD — Completed
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) — Completed
• Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease — Completed
• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder — Completed
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
• The Efficacy and Safety of PRC-063 in Adult ADHD Patients — Completed
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment — Stopped early
• Experimental Medication For the Treatment of Generalized Anxiety Disorder — Completed
• Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder — Stopped early
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed